Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Drugs

06-09-2024 | Alzheimer's Disease | AdisInsight Report

Donanemab: First Approval

Author: Connie Kang

Published in: Drugs

Login to get access

Abstract

Donanemab (donanemab-azbt; KisunlaTM) is an amyloid β-directed antibody developed by Eli Lilly and Company for the treatment of Alzheimer’s disease. Donanemab recently received approval in the USA for the treatment of adults with early symptomatic Alzheimer’s disease (patients with mild cognitive impairment or mild dementia stage of disease). This article summarizes the milestones in the development of donanemab leading to this first approval for Alzheimer’s disease.
Appendix
Available only for authorised users
Literature
1.
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–27.CrossRefPubMedPubMedCentral
2.
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704.CrossRefPubMed
3.
4.
5.
Gueorguieva I, Willis BA, Chua L, et al. Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer’s disease. Clin Pharmacol Ther. 2023;113(6):1258–67.CrossRefPubMed
6.
Sato S, Hatakeyama N, Fujikoshi S, et al. Donanemab in Japanese patients with early Alzheimer’s disease: subpopulation analysis of the TRAILBLAZER-ALZ 2 randomized trial. Neurol Ther. 2024;13(3):677–95.CrossRefPubMedPubMedCentral
7.
Salloway S, Lee E, Papka M, et al. TRAILBLAZER-ALZ 4: topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease [abstract]. BJPsych Open. 2023;9(Suppl. 1):S67.CrossRefPubMedCentral
8.
Pain A, Ferguson MB, Wang H, et al. TRAILBLAZER-ALZ 4: directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease - results from 12-months [abstract]. Alzheimer’s Dement. 2023;19(Suppl. 24): e082529.CrossRef
Metadata
Title
Donanemab: First Approval
Author
Connie Kang
Publication date
06-09-2024
Publisher
Springer International Publishing
Published in
Drugs
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-024-02087-4